Physician profile
Lee V Gray
NPI 1114145554
$883.89
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $83.18 · 2021: $40.38 · 2022: $130 · 2023: $62.06 · 2024: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $318.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $200.77 | 2019-2020 | |
| Genzyme Corporation | $140.38 | 2024 | |
| Grt US Holding, INC. | $116.66 | 2022 | |
| Collegium Pharmaceutical, INC. | $112.44 | 2023-2024 | Xtampza, Belbuca |
| Scilex Pharmaceuticals INC. | $70.08 | 2021-2024 | Ztlido |
| Daiichi Sankyo INC. | $40.62 | 2019 | |
| Indivior INC. | $36.36 | 2019-2021 | |
| Pfizer INC. | $29.39 | 2019 | |
| Nevro Corp. | $25.61 | 2024 | Senza |
| Pacira Therapeutics, INC. | $20.07 | 2019 | |
| Abbott Laboratories | $18.51 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.18 | 2019 | |
| Orexo US, INC. | $16.43 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.52 | 2019 | |
| Forte Bio-Pharma LLC | $13.98 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.